Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Capital Expenditures of $761000.0 for Q1 2026, up 78.22% year-over-year from $427000.0 in Q1 2025, and up 187.88% quarter-over-quarter from -$866000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $761000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 78.22% year-over-year to $761000.0; the TTM figure through Mar 2026 stood at $703000.0 (down 55.02% YoY), while the FY2025 annual figure was $369000.0, down 71.22% from the prior year.
- Capital Expenditures for Q1 2026 stood at $761000.0, up from -$866000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $857000.0 in Q3 2025, with the low at -$866000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $126000.0 (2023), against an average of $186411.8.
- Peak annual rise in Capital Expenditures reached 800.0% in 2023, while the deepest fall reached 359.68% in 2023.
- Protalix BioTherapeutics' Capital Expenditures stood at -$62000.0 in 2022, then slumped by 359.68% to -$285000.0 in 2023, then soared by 249.12% to $425000.0 in 2024, then plunged by 303.76% to -$866000.0 in 2025, then jumped by 187.88% to $761000.0 in 2026.
- Business Quant data shows PLX's Capital Expenditures at $761000.0 in Q1 2026, -$866000.0 in Q4 2025, and $857000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 593,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 593,000.00 |
| Jun 30, 2026 | 593,000.00 |
| Mar 31, 2026 | 761,000.00 |
| Mar 31, 2026 | 761,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Sep 30, 2025 | 857,000.00 |
| Sep 30, 2025 | 857,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |